Clinical Trial AdvancementsPatient enrollment in the phase 3 epilepsy program is progressing, demonstrating advancement in the company's clinical trials.
Financial StabilityThe company ended the year with a robust cash reserve, ensuring a financial runway into 2027 and showcasing strong financial planning.
Stock PerformanceAnalysts maintain a Buy rating with increased price targets, reflecting confidence in potential future revenues and the company's stock performance.